Olema Oncology plans to start a Phase III trial studying palazestrant with a CDK4/6 inhibitor from Novartis in mid-2025.
The European Commission (EC) has granted approval to Novartis' Kisqali (ribociclib), plus an aromatase inhibitor to treat ...
The European Commission has cleared use of CDK4/6 inhibitor Kisqali (ribociclib) to reduce the risk of recurrence in patients ...
Olema Pharmaceuticals prepares for its OPERA-02 study, targeting ER+/HER2- breast cancer. Read why OLMA stock could benefit ...
Novartis’ Kisqali (ribociclib) has been approved by the European Commission (EC) to reduce the risk of disease recurrence in ...
Novartis Kisqali receives European approval in a broad population of patients with HR+/HER2- early breast cancer at high risk of recurrence: Basel Thursday, November 28, 2024, 09: ...
Novartis has secured European Commission approval for Kisqali® (ribociclib) in combination with endocrine therapy (ET) as an ...
Winrevair was approved to treat PAH WHO Group 1 in the United States in March based on data from the STELLAR study.
Novartis' CDK4/6 inhibitor Kisqali has claimed a broad FDA approval in early breast cancer that could give it an edge over class rival Verzenio from Eli Lilly. The US regulator has cleared Kisqali ...
Novartis (NVS) said that the European Commission has approved Kisqali (ribociclib) in combination with an aromatase inhibitor for the ...